Nk/monocyte engagers
AssigneeBiomolecular Holdings LLC
InventorDaniel J. Capon
Life of this patent
Estimating the term…
Abstract
This invention provides a tetrahedral antibody comprising a first, second, third, fourth, fifth, and sixth domain, wherein each of the first and second domains are an Fc domain of an IgG antibody comprising S239D and I332E mutations on both the first polypeptide chain and second polypeptide chain of the domain; the third domain and fourth domains are each a Fab domain comprising the V region of a Fab domain of FMC59 or a variant thereof with at least 95% identity to said V region; and the fifth and sixth domains are each a Fab domain comprising the V region of a Fab domain of Rituximab or a variant thereof with at least 95% identity to said V region.
Claims11
A tetrahedral antibody comprising a first, second, third, fourth, fifth, and sixth domain, wherein:
- a) each of the first and second domains are an Fc domain of an IgG antibody and comprise:
- i) a first polypeptide chain comprising a first N-terminus and a first C-terminus of the domain,
- ii) a second polypeptide chain comprising a second N-terminus and a second C-terminus of the domain, and
- iii) S239D and I332E mutations on both the first polypeptide chain and second polypeptide chain of the domain;
- b) the first domain and the second domain are joined to each other by a non-covalent linkage between a first collectrin-like domain polypeptide attached by a peptide bond or via a peptide linker to the first N-terminus of the first domain, and a second collectrin-like domain polypeptide attached by a peptide bond or via a peptide linker to the first N-terminus of the second domain;
- c) the third domain is a Fab domain comprising the V region of a Fab domain of FMC59 or a variant thereof with at least 95% identity to said V region, which Fab domain is attached at its C-terminus by a peptide bond or via a peptide linker to the N-terminus of the first collectrin-like domain polypeptide;
- d) the fourth domain is a Fab domain comprising the V region of a Fab domain of FMC59 or a variant thereof with at least 95% identity to said V region, which Fab domain is attached at its C-terminus by a peptide bond or via a peptide linker to the N-terminus of the second collectrin-like domain polypeptide;
- e) the fifth domain is a Fab domain comprising the V region of a Fab domain of Rituximab or a variant thereof with at least 95% identity to said V region, which Fab domain is attached at its C-terminus by a peptide bond or via a peptide linker to the second N-terminus of the first domain;
- and
- f) the sixth domain is a Fab domain comprising the V region of a Fab domain of Rituximab or a variant thereof with at least 95% identity to said V region, which Fab domain is attached at its C-terminus by a peptide bond or via a peptide linker to the second N-terminus of the second domain.
Dependencies are inferred from the claim text.